C-Path (Critical Path TRXA-Therapeutic accelerator)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Monday 25th, March 2024
External Deadline: Sunday 31st, March 2024
Description
Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) has announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants (BRIDGe). These BRIDGe awards are designed to support academic researchers in delving into drug development approaches and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. For more information please visit TRxA | Critical Path Institute (c-path.org).
TRxA’s focus is translating early-stage novel therapeutics into Investigational New Drug (IND) supporting data packages that garner interest for licensing opportunities; we are helping “BRIDGe” (Breakthrough Research and Innovation in Drug Development Grants) the drug development valley of death. Projects eligible for TRxA BRIDGe funding and support include early lead optimization through IND-enabling studies of small molecule therapeutics. Biologics, including natural peptides or antibodies, cell and gene therapy applications, and diagnostic and medical devices are not eligible at this time; nor are drug repurposing initiatives.
TRxA funding and support is reserved for faculty at universities and non-profit institutions, anywhere around the world. Awards are not limited to specific therapeutic indications. TRxA offers funding and support for three (3) types of translational projects, ranging from early lead optimization to IND-enabling studies.
See here for more information.
If you are interested, there is an informational webinar on January 30, 2024 at 10:00 AM US EST. More information, including a link to register, is available here: Webinar Registration – Zoom.